Sponsors

Large-scale soft tissue sarcoma study: introducing a veterinary partnership

The Veterinary Pathology Group – a member of SYNLAB UK and Ireland – has announced that it is partnering with Fitzpatrick Referrals to conduct a canine soft tissue sarcoma study to improve clinical practice and subsequent patient outcomes.

A soft tissue sarcoma (STS) study, which is being led by Tom Cave, the team of pathologists at Veterinary Pathology Group (VPG) Histology, and Jonathan Bray from Fitzpatrick Referrals, will be the largest piece of research into these canine tumours undertaken to date. The research will look at what happened to over 15,000 dogs with STS after surgery to remove their tumours.

            Soft tissue sarcoma is one of the most common malignant tumours in dogs. It can metastasise and is especially prone to local recurrence if surgery fails to effect completely removal. Unlike in some tumours, these problems may take over two years to develop. Tom commented: “To study STS you need to allow a long follow-up time to fully understand the outcome of treatment.  With some tumours you can revisit the patient one year on and understand what happened, but with STS you need to continue follow-up for at least two to three years or you risk overestimating the success of treatment.”

Study objectives

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

Hyatt Regency, Vancouver, Canada
19-23 November, 2024

11th Digital Pathology & AI Congress: Europe

Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024

Microbiology Society Annual Conference 2025

Liverpool Arena and Convention Centre
31 March - 3 April, 2025

BSMT Annual Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025